Literature DB >> 33744485

The efficacy of telemedical care for heart failure: A meta-analysis of randomized controlled trials.

XuHui Ma1, Jie Li1, XiuZan Ren2.   

Abstract

INTRODUCTION: The efficacy of telemedical care for the treatment of heart failure remains controversial. We conduct a systematic review and meta-analysis to explore the impact of telemedical care on heart failure.
METHODS: We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through October 2020 for randomized controlled trials (RCTs) assessing the effect of telemedical care on heart failure. This meta-analysis is performed using the random-effect model.
RESULTS: Four RCTs involving 2516 patients are included in the meta-analysis. Overall, compared with control group for heart failure, telemedical care demonstrates no significant influence on cardiovascular death (OR = 0.74; 95% CI = 0.54 to 1.00; P = 0.05), mortality (OR = 0.86; 95% CI = 0.61 to 1.20; P = 0.38), hospital stay for heart failure (SMD = -1.57; 95% CI = -6.31 to 3.16; P = 0.52) or hospital stay for any readmission (SMD = -0.65; 95% CI = -8.98 to 7.68; P = 0.88), but can reduce the days lost due to death or heart failure readmissions (SMD = -6.50; 95% CI = -8.44 to -4.56; P < 0.00001).
CONCLUSIONS: Telemedical care may provide no additional benefits for heart failure.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Heart failure; Meta-analysis; Randomized controlled trials; Telemedical care

Year:  2021        PMID: 33744485     DOI: 10.1016/j.ajem.2021.01.032

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  1 in total

1.  Efficacy of telemedicine for the management of cardiovascular disease: a systematic review and meta-analysis.

Authors:  Pei Xuan Kuan; Weng Ken Chan; Denisa Khoo Fern Ying; Mohd Aizuddin Abdul Rahman; Kalaiarasu M Peariasamy; Nai Ming Lai; Nicholas L Mills; Atul Anand
Journal:  Lancet Digit Health       Date:  2022-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.